NIAID and MTN Launch Phase III Study of Dapivirine Ring

On July 24 at the XIX International AIDS Conference, IPM's partners NIAID and MTN announced the launch of ASPIRE, a Phase III study of the monthly dapivirine ring.

ASPIRE now joins IPM’s ongoing Ring Study in the field to help determine whether the ring protects against HIV infection and is safe for long-term use.

Together, these sister studies help make up a broader dapivirine ring licensure program designed to provide the strength of evidence needed to submit the product for licensure, pending study results in 2015.

View NIAID's press release and Q&A as well as MTN's press release and Q&A.